Scancell
BioTech/Drugs - Nottingham, Oxford, Nottingham
Scancell Details
Scancell is developing therapeutic vaccines for the treatment of cancer and infectious diseases based on its ImmunoBody® and Moditope™ technology platforms. Scancell’s first cancer vaccine SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012.
Website:
http://www.scancell.co.uk/
Employees:
57
HQ:
+44 1865 582066
Location:
Nottingham, Oxford, Nottingham
Revenue:
2.5 - 5 Million
Scancell Technologies
Frameworks and Programming Languages
ASP.NET
Email Providers
Outlook
Web Performance Monitoring
New Relic
Online Video Platforms
YouTube
Other
Google Maps